Target gene for ovarian cancer treatment and application thereof
Lnc-GPAT3-1 is used as a diagnostic marker and therapeutic target for ovarian cancer, enhancing early detection and treatment efficacy through specific primer and siRNA-based methods.
Patent Information
- Application Number
- CN202411488517.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-24
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-10-24
AI Technical Summary
Current methods for diagnosing and treating ovarian cancer are inadequate due to the lack of effective early detection and targeted therapies, leading to high mortality rates despite its lower incidence compared to other gynecological cancers.
Utilization of lnc-GPAT3-1 as a diagnostic marker and therapeutic target, employing specific primers and siRNA to detect and inhibit its expression in ovarian cancer patients, using a kit and drug formulation.
Lnc-GPAT3-1 demonstrates high diagnostic sensitivity (90.5%) and specificity (77.8%) for ovarian cancer, and inhibiting its expression significantly reduces cancer cell proliferation, offering a promising treatment approach.
Smart Images

Figure CN119082308A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of ovarian cancer treatment, and in particular to a target gene for ovarian cancer treatment and application thereof. Background Art
[0002] Ovarian cancer is a type of malignant tumor of the ovary, which refers to a malignant tumor that grows on the ovary. 90% to 95% of them are primary ovarian cancers, and the other 5% to 10% are primary cancers from other parts of the body that have metastasized to the ovary. Since there are no symptoms in the early stages of ovarian cancer, and even if there are symptoms, they are not specific, and the role of screening is limited, early diagnosis is difficult. When seeking medical treatment, 60% to 70% of cases are already in the late stage, and the treatment effect of late-stage cases is poor. Therefore, although the incidence of ovarian cancer is lower than cervical cancer and endometrial cancer and ranks third among gynecological malignancies, its mortality rate exceeds the sum of cervical cancer and endometrial cancer, ranking first among gynecological cancers, and is the biggest disease that seriously threatens women's health.
[0003] At present, the study of lncRNAs (long non-coding RNAs) has become a hot topic in many cancers. Initially, it was found that lncRNAs would be abnormally expressed in the occurrence and development of many cancers: some lncRNAs were expressed in large quantities as if they were released from control, while some lncRNAs were downregulated as if they were suppressed. This discovery indicates that lncRNAs may be participants in the occurrence and development of tumors. Later, many experimental results also showed that lncRNAs have the ability to promote or inhibit tumor development and progression. Based on the role of lncRNAs in regulating gene expression and the high possibility that lncRNAs are involved in tumorigenesis, lncRNAs are considered to be a promising tissue or blood-based cancer biomarker, on which new methods of cancer treatment will be developed.
[0004] In summary, it is necessary to develop new l ncRNA markers for clinical diagnosis and targeted treatment of ovarian cancer. Summary of the invention
[0005] In view of the technical problems existing in the prior art, the present invention provides a target gene for the treatment of ovarian cancer and its application. In particular, it relates to the application of lnc-GPAT3-1 as an auxiliary diagnostic marker and potential therapeutic target for ovarian cancer. The present invention finds that lnc-GPAT3-1 is used as an auxiliary diagnostic marker for ovarian cancer, and lnc-GPAT3-1 can be used as a therapeutic target. Targeted inhibition of its expression can achieve the treatment of ovarian cancer patients, which has a broad application prospect.
[0006] One of the purposes of the present invention is to provide a use of lnc-GPAT3-1 as a diagnostic marker in the preparation of a reagent for auxiliary diagnosis and / or evaluation of ovarian cancer, wherein the nucleotide sequence of the lnc-GPAT3-1 is shown in SEQ ID No.1.
[0007] Preferably, the expression level of lnc-GPAT3-1 in ovarian cancer patients is detected to assist in the diagnosis and / or assessment of ovarian cancer.
[0008] Another object of the present invention is a kit for assisting in the diagnosis and / or evaluation of ovarian cancer, characterized in that it contains primers for specifically amplifying lnc-GPAT3-1.
[0009] Preferably, the primers for specifically amplifying lnc-GPAT3-1 are: the upstream primer sequence is SEQ ID No.2, and the downstream primer sequence is SEQ ID No.3.
[0010] Preferably, the test sample in the kit is blood.
[0011] One of the purposes of the present invention is to use lnc-GPAT3-1 in preparing a kit for assisting in the diagnosis and / or evaluation of ovarian cancer.
[0012] One of the purposes of the present invention is to use lnc-GPAT3-1 as a therapeutic target in the preparation of a drug for treating ovarian cancer.
[0013] Preferably, the use of lnc-GPAT3-1 siRNA in the preparation of a drug for treating ovarian cancer, wherein the drug uses lnc-GPAT3-1 as a therapeutic target, and the lnc-GPAT3-1 siRNA includes any one or more of siRNA1-3, and their sequences are shown in SEQ ID No.4-9.
[0014] One of the purposes of the present invention is a drug for treating ovarian cancer, which contains a nucleic acid, a biologically active functional fragment or a variant having at least one of the sequences shown in SEQ ID No. 4-9.
[0015] Furthermore, the drug includes a pharmaceutically acceptable carrier or excipient.
[0016] The advantages of the present invention are as follows: The present invention found that the expression level of lnc-GPAT3-1 in the blood of ovarian cancer patients was significantly higher than that of healthy people, and the area under the AUC curve was calculated and analyzed to be 0.857, and the diagnostic sensitivity could reach 90.5%, and the specificity was as high as 77.8%. It was confirmed that the lnc-GPAT3-1 gene has good application prospects in the diagnosis of ovarian cancer patients. In addition, it was found that knocking down lnc-GPAT3-1 would significantly inhibit the expression of lnc-GPAT3-1 in ovarian cancer patients and effectively inhibit the proliferation ability of ovarian cancer, which can be used as a feasible solution for the treatment of ovarian cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 .l Expression of nc-GPAT3-1 gene in ovarian cancer patients;
[0018] Figure 2 . Analysis of lnc-GPAT3-1 gene expression in ovarian cancer cells treated with interfering siRNA;
[0019] Figure 3 .Analysis of proliferation ability of ovarian cancer cells treated with interfering siRNA. DETAILED DESCRIPTION
[0020] The present invention is further described in detail below in conjunction with specific embodiments so that those skilled in the art can understand the present invention more clearly.
[0021] The following embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. Based on the specific embodiments of the present invention, all other embodiments obtained by ordinary technicians in the field without creative work belong to the protection scope of the present invention.
[0022] In the examples of the present invention, unless otherwise specified, all raw material components are commercially available products well known to those skilled in the art; in the examples of the present invention, unless otherwise specified, the technical means used are conventional means well known to those skilled in the art.
[0023] Example 1 Screening and determination of ncRNA biomarkers in ovarian cancer
[0024] Extract ovarian cancer samples from the TCGA database, screen all l ncRNAs in the above website, select the gene expression profile of ovarian cancer mRNA Expression z-Scores (RNA Seq V2RSEM), sort the generated results, and select the l ncRNAs with the largest change rate in ovarian cancer genetics as candidate biomarkers. Compare the results of the preliminary screening of the TCGA database with the results of ovarian cancer chip sequencing in the GEO database, remove some results that do not have obvious differential expression, and finally determine the target l nc-GPAT3-1, whose sequence is shown in SEQ ID NO.1.
[0025] Example 2 Analysis of the expression of nc-GPAT3-1 gene in clinical ovarian cancer patients
[0026] 1. Preparation of experimental materials:
[0027] All trial subjects were patients diagnosed with ovarian cancer by clinicians from January 2021 to December 2022. Blood samples from 80 patients were collected for backup; blood samples from 80 healthy people were collected as controls during the same period.
[0028] 2. Test methods
[0029] 1) Extraction of total RNA from blood genes: The extraction steps were carried out according to the instructions of the miRNeasy-SerumPl asma-217184 kit, and the serum sample was 200 μL.
[0030] 2) Use primer design software to obtain the above-mentioned lnc-GPAT3-1 gene specific primers. Among them, the specific amplification primers are as follows:
[0031] Upstream primer: 5'-GCTGGCTGCAGTGAAGATGA-3' (SEQ ID NO. 2);
[0032] Downstream primer: 5'-GTCTGCTCTGGCATGCTACT-3' (SEQ ID NO. 3).
[0033] 3) Use the M-MLV reverse transcription kit to complete the reverse transcription of the total RNA in step 1).
[0034] 4) PCR quantitative detection and analysis of lnc-GPAT3-1 gene expression, using 2 -ΔΔCt Method calculation.
[0035] Among them, the 25 μL PCR reaction system includes: 10 μL 10×PCR Buffer, 2 μL SYBR Green I fluorescent dye, 2 μL dNTP, 2 μL of upstream and downstream primers of l nc-GPAT3-1, 2 μL Taq DNA polymerase and 5 μL cDNA;
[0036] The PCR reaction program was pre-denaturation at 94°C for 10 min; 94°C for 30 s, 58°C for 45 s, and extension at 72°C for 30 s, for a total of 35 cycles; and extension at 72°C for 10 min.
[0037] Results Figure 1 Compared with healthy people, the expression of lnc-GPAT3-1 in 80 pairs of ovarian cancer patient blood samples was significantly upregulated. The area under the AUC curve was calculated to be 0.857, with a diagnostic sensitivity of 90.5% and a specificity of 77.8%. The experimental data analysis further confirmed that the lnc-GPAT3-1 gene has a good application prospect in the diagnosis of ovarian cancer patients.
[0038] Example 3 Analysis of the effect of inhibiting the expression of nc-GPAT3-1 on the improvement of ovarian cancer
[0039] 1. Preparation of experimental materials:
[0040] Ovarian cancer OVCAR-3 cells were used as the research object and cultured with OVCAR-3 cell-specific culture medium (purchased from Beina Chuanglian Biotechnology Co., Ltd., No. BNCC360841) and kept for later use after stable passage.
[0041] 2. Test methods
[0042] 1) Design of lnc-GPAT3-1 interference fragment: Three groups of siRNA were synthesized in Shanghai Jima Biotechnology, and the sequences were siRNA1 (SEQ ID NO.4-5), siRNA2 (SEQ ID NO.6-7), and siRNA3 (SEQ ID NO.8-9).
[0043] 2) Interference efficiency verification: OVCAR-3 cells were divided into four parts, three of which were transfected with siRNA1-3, respectively, and the fourth was not transfected with siRNA at the same time.
[0044] 3) 24 hours after transfection, the relative expression of lnc-GPAT3-1 was quantitatively analyzed by the method described in Example 2, and CCK8 was used to detect the changes in OVCAR-3 cell proliferation.
[0045] As shown in the result figure, the three groups of siRNA can significantly reduce the expression of lnc-GPAT3-1, and compared with the control group, the proliferation ability of OVCAR-3 cells in the experimental group was significantly weakened, which was significantly different from the control group. It further confirmed that targeted downregulation of the lnc-GPAT3-1 gene is used for the treatment of ovarian cancer.
[0046] The above embodiments are intended to illustrate the essential content of the present invention, but are not intended to limit the protection scope of the present invention. Those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and protection scope of the technical solution of the present invention.
Claims
1. Use of lnc-GPAT3-1 as a diagnostic marker in the preparation of a reagent for auxiliary diagnosis and / or evaluation of ovarian cancer, wherein the nucleotide sequence of the lnc-GPAT3-1 is shown in SEQ ID No.
1.
2. The use according to claim 1, characterized in that The expression level of lnc-GPAT3-1 in ovarian cancer patients is detected to assist in the diagnosis and / or evaluation of ovarian cancer.
3. A kit for assisting in the diagnosis and / or assessment of ovarian cancer, characterized in that: Contains primers for specific amplification of lnc-GPAT3-1.
4. The kit according to claim 3, characterized in that The primers for specifically amplifying lnc-GPAT3-1 are: the upstream primer sequence is SEQ ID No.2, and the downstream primer sequence is SEQ ID No.
3.
5. The kit according to claim 4, characterized in that The test sample in the kit is blood.
6. Use of lnc-GPAT3-1 in preparing a kit for auxiliary diagnosis and / or evaluation of ovarian cancer.
7. Application of lnc-GPAT3-1 as a therapeutic target in the preparation of drugs for the treatment of ovarian cancer.
8. Use of siRNA targeting lnc-GPAT3-1 in the preparation of a drug for treating ovarian cancer, characterized in that: The drug takes lnc-GPAT3-1 as a therapeutic target, and the lnc-GPAT3-1 targeting siRNA includes any one or more of siRNA1-3, and their sequences are shown in SEQ ID No.4-9 in sequence.
9. A drug for treating ovarian cancer, characterized in that: The therapeutic drug contains a nucleic acid, a biologically active functional fragment or a variant having at least one of the sequences shown in SEQ ID No. 4-9.
10. The therapeutic drug according to claim 9, characterized in that The medicine includes a pharmaceutically acceptable carrier or excipient.
Citation Information
Patent Citations
Molecular marker related to ovarian cancer as well as screening method and application of molecular marker
CN118240936A
Cited By
Protease 3 molecular marker applied to ovarian cancer immunotherapy and molecular diagnosis
CN119842909A
